Enliven Therapeutics, Inc. (ELVN)
Automate Your Wheel Strategy on ELVN
With Tiblio's Option Bot, you can configure your own wheel strategy including ELVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ELVN
- Rev/Share 0.0061
- Book/Share 9.3748
- PB 2.1062
- Debt/Equity 0.0008
- CurrentRatio 32.5831
- ROIC -0.2336
- MktCap 1169604948.0
- FreeCF/Share -1.358
- PFCF -16.5289
- PE -10.2661
- Debt/Assets 0.0007
- DivYield 0
- ROE -0.2915
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ELVN | Goldman | -- | Buy | -- | $37 | June 16, 2025 |
| Initiation | ELVN | BTIG Research | -- | Buy | -- | $42 | Dec. 13, 2024 |
| Initiation | ELVN | H.C. Wainwright | -- | Buy | -- | $37 | Sept. 9, 2024 |
News
Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 106.5% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 102.4% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Published: June 13, 2025 by: PRNewsWire
Sentiment: Neutral
BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,780,263 shares of Enliven's common stock at a price to the public of $19.659 per pre-funded warrant, which represents the per share public …
Read More
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress
Published: May 14, 2025 by: PRNewsWire
Sentiment: Neutral
Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff Presentation at EHA will include updated data with additional patients and longer treatment duration Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET BOULDER, Colo.
Read More
About Enliven Therapeutics, Inc. (ELVN)
- IPO Date 2020-03-12
- Website https://www.enliventherapeutics.com
- Industry Biotechnology
- CEO Samuel S. Kintz
- Employees 62